Who are Asparlas's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Asparlas, ASPARAGINASE ERWINIA CHRYSANTHEMI, PEGASPARGASE, Elspar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/calaspargase-pegol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Asparlas — Competitive Intelligence Brief

Asparlas (CALASPARGASE PEGOL) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Asparagine-specific Enzyme [EPC]. Area: Oncology.

marketed Asparagine-specific Enzyme [EPC] Oncology Enzyme Live · refreshed every 30 min

Target snapshot

Asparlas (CALASPARGASE PEGOL) — Servier Pharma Llc . Asparlas depletes asparagine, an amino acid that cancer cells rely on for growth.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Asparlas TARGET	CALASPARGASE PEGOL	Servier Pharma Llc	marketed	Asparagine-specific Enzyme [EPC]		2018-01-01
Asparlas	calaspargase	Pfizer	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2018-01-01
ASPARAGINASE ERWINIA CHRYSANTHEMI	ASPARAGINASE ERWINIA CHRYSANTHEMI		marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2011-01-01
PEGASPARGASE	PEGASPARGASE		marketed	Asparagine-specific Enzyme [EPC]		1994-01-01
Elspar	ASPARAGINASE	Merck & Co.	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Asparagine-specific Enzyme [EPC] class)

· 2 drugs in this class
Merck & Co. · 1 drug in this class
Pfizer · 1 drug in this class
Servier Pharma Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Asparlas — Competitive Intelligence Brief. https://druglandscape.com/ci/calaspargase-pegol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab